Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G H Jackson

Showing results (51-60 of 70) with videos related to

Pageof 7
Sort By:
Leukemia|August 1, 1997
The use of an all oral chemotherapy (idarubicin and etoposide) in the treatment of acute myeloid leukaemia in the elderly: a report of toxicity and efficacyG H Jackson, P R Taylor, A Iqbal, et al.
Leukemia|August 1, 1991
Alpha interferon gene deletions in adults, children and infants with acute lymphoblastic leukemiaP G Middleton, R A Prince, I K Williamson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 11, 2009
The role of an all-oral chemotherapy containing lomustine (CCNU) in advanced,fs progressive Hodgkin lymphoma: a patient-friendly palliative option which can result in long-term disease controlS J Proctor, A L Lennard, G H Jackson, et al.
Hematology (Amsterdam, Netherlands)|April 29, 2010
Facilities for the treatment of adults with haematological malignancies--'Levels of Care': BCSH Haemato-Oncology Task Force 2009F Matthey, A Parker, S A J Rule, et al.
European Journal of Cancer (Oxford, England : 1990)|April 9, 2002
A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin's disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle Lymphoma Group study (SNLG HD III)S J Proctor, M Mackie, A Dawson, et al.
International Journal of Laboratory Hematology|February 21, 2008
British Society for Haematology, Slide session, Annual Scientific Meeting, Bournemouth, 2007M Bhavnani, J Braithwaite, J Burthem, et al.
Leukemia & Lymphoma|November 17, 2006
The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non-Hodgkin's lymphoma: Results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trialP R A Taylor, J M White, R J Prescott, et al.
Blood Cancer Journal|March 19, 2024
Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometryH V Giles, M T Drayson, B Kishore, et al.
European Journal of Haematology. Supplementum|August 7, 2001
High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacyS J Proctor, P R Taylor, B Angus, et al.
Leukemia|August 10, 2021
Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugsJ R Jones, A Barber, Y-V Le Bihan, et al.
Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
Leukemia|August 1, 1997
The use of an all oral chemotherapy (idarubicin and etoposide) in the treatment of acute myeloid leukaemia in the elderly: a report of toxicity and efficacyG H Jackson, P R Taylor, A Iqbal, et al.
Leukemia|August 1, 1991
Alpha interferon gene deletions in adults, children and infants with acute lymphoblastic leukemiaP G Middleton, R A Prince, I K Williamson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 11, 2009
The role of an all-oral chemotherapy containing lomustine (CCNU) in advanced,fs progressive Hodgkin lymphoma: a patient-friendly palliative option which can result in long-term disease controlS J Proctor, A L Lennard, G H Jackson, et al.
Hematology (Amsterdam, Netherlands)|April 29, 2010
Facilities for the treatment of adults with haematological malignancies--'Levels of Care': BCSH Haemato-Oncology Task Force 2009F Matthey, A Parker, S A J Rule, et al.
European Journal of Cancer (Oxford, England : 1990)|April 9, 2002
A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin's disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle Lymphoma Group study (SNLG HD III)S J Proctor, M Mackie, A Dawson, et al.
International Journal of Laboratory Hematology|February 21, 2008
British Society for Haematology, Slide session, Annual Scientific Meeting, Bournemouth, 2007M Bhavnani, J Braithwaite, J Burthem, et al.
Leukemia & Lymphoma|November 17, 2006
The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non-Hodgkin's lymphoma: Results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trialP R A Taylor, J M White, R J Prescott, et al.
Blood Cancer Journal|March 19, 2024
Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometryH V Giles, M T Drayson, B Kishore, et al.
European Journal of Haematology. Supplementum|August 7, 2001
High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacyS J Proctor, P R Taylor, B Angus, et al.
Leukemia|August 10, 2021
Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugsJ R Jones, A Barber, Y-V Le Bihan, et al.
Pageof 7